PCL 016

Drug Profile

PCL 016

Alternative Names: NV 02; NVTL 0001; PCL-016

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Novactyl
  • Developer Novactyl; Upsher-Smith
  • Class Antiacnes; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase II Acne
  • No development reported Herpes simplex virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (Topical)
  • 27 May 2004 Data presented at the 65th Annual Meeting of The Society for Investigative Dermatology (SID-2004) have been added to the adverse events and Skin Disorders therapeutic trials sections
  • 14 Nov 2002 Phase-II clinical trials in Acne in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top